What is the primary mechanism of BPC-157 in tissue repair research?

BPC-157 is primarily studied for its activity on the nitric oxide synthesis pathway and VEGF-driven angiogenesis. In preclinical models, it promotes endothelial nitric oxide production, upregulates VEGF at injury sites, and interacts with growth factor receptors to support cellular proliferation. These combined effects have been documented across tendon, gut, CNS, and vascular repair models.

How does BPC-157 differ from TB-500 in repair research?

BPC-157 acts through nitric oxide and growth factor signaling (VEGF, EGF receptor) to promote angiogenesis and tissue-level repair. TB-500 acts through actin sequestration and G-actin regulation to promote cellular migration and wound closure at the cytoskeletal level. The two compounds target different phases and mechanisms of the repair process, which is why they are often co-studied in repair research designs.

Does BPC-157 have human clinical trial data?

The majority of published BPC-157 research is preclinical, conducted in rodent injury and disease models. Some early-phase human work has been published in Eastern European literature, but robust randomized controlled trial data in human subjects is limited compared to the extensive animal model literature. Researchers sourcing BPC-157 typically reference the preclinical body of work from the Sikiric laboratory and affiliated groups.

What research models have been used to study BPC-157?

BPC-157 has been studied in Achilles tendon transection models, gastric ulcer and IBD paradigms, colitis models, spinal cord and TBI injury protocols, peripheral nerve crush models, vascular anastomosis studies, corneal wound models, and systemic inflammation paradigms. This breadth of models has contributed to its profile as one of the most investigated synthetic peptides in preclinical repair biology.

Compound Reference

BPC-157

A gastric pentadecapeptide investigated across tissue repair, angiogenesis, and cytoprotection research.

PentadecapeptideC₆₂H₉₈N₁₆O₂₂Approx. 4 hours (preclinical)

Tissue RepairAngiogenesisGut CytoprotectionConnective TissueNeuroprotection

Overview

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has been studied extensively in preclinical models for its effects on tissue repair, wound healing, and organ cytoprotection. Research across rodent models has documented its influence on nitric oxide synthesis pathways, VEGF upregulation, and growth factor receptor signaling relevant to angiogenesis and connective tissue recovery. Its research profile spans gastric ulcer models, tendon and ligament injury paradigms, CNS ischemia protocols, and systemic inflammatory models.

Quick Reference

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Origin: Derived from human gastric juice protective protein
Primary mechanism: Nitric oxide pathway, VEGF upregulation, GH receptor interaction
Research models: Tendon, gut, CNS, vascular, systemic injury paradigms
Purity standard: >=98% by HPLC

Mechanism

How It Works

BPC-157 acts through the nitric oxide synthesis pathway, promoting endothelial nitric oxide production and VEGF-driven angiogenesis at injury sites. It also modulates the growth hormone receptor and interacts with EGF receptor signaling, contributing to cellular proliferation and tissue restoration in multiple organ systems studied in preclinical research.

Research Highlights

Key findings from the published preclinical literature.

Tendon and Ligament Repair Models

Sikiric et al. documented accelerated Achilles tendon healing and collagen organization in rodent transection models, with BPC-157-treated animals showing improved tensile strength relative to controls.

Gastrointestinal Cytoprotection

Preclinical studies in gastric ulcer, inflammatory bowel, and fistula models have consistently documented BPC-157 activity in reducing mucosal lesion area and restoring gut epithelial integrity via nitric oxide pathways.

Angiogenesis and Wound Vascularization

BPC-157 has been studied for its capacity to upregulate VEGF and promote new vessel formation in wound bed models, contributing to tissue oxygenation and accelerated macroscopic healing in preclinical studies.

CNS and Neuroprotective Models

Research examining BPC-157 in rodent ischemia, spinal cord injury, and traumatic brain injury paradigms has documented neuroprotective outcomes attributed to its nitric oxide modulation and growth factor signaling activity.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Source This Compound

BPC-157 is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

View BPC-157 Product Sourcing Guide

All compounds are strictly for in-vitro research use only and not intended for human consumption.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research